Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial
Part of paid clinical trials in St Louis, Missouri.
- Sponsor
- Washington University School of Medicine
- Study ID
- NCT06240754
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- CCUS Clonal Cytopenia of Undetermined Significance
- Clonal Cytopenia of Undetermined Significance
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Enasidenib — DRUGProvided by BMS.
Study Details
Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.
Key Dates
- Start date
- Oct 10, 2024
- Status verified
- May 2026
- Primary completion
- Jan 31, 2028
- Completion
- Feb 28, 2029
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: EnasidenibParticipants will receive enasidenib 100 mg daily for 18 cycles (each cycle is 28 days). Participants will continue treatment with enasidenib until confirmed progression to AML or MDS, development of unacceptable toxicity, or suspicion of disease progression, provided the patient is deriving clinical benefit, which will be determined at the discretion of the principal investigator.
Primary Outcome Measure
Best hematologic response [ Time Frame: Up to 18 cycles (each cycle is 28 days) of treatment (up to approximately 17 months) ]
Central Contacts
- Giulia Petrone, M.D.314-362-6826
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Washington University School of Medicine | St Louis | Missouri | 63110 | Giulia Petrone, M.D. (PRINCIPAL_INVESTIGATOR) |
Find similar trials in St Louis, MO
By research site
Related Studies
- Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)PHASE2 · Recruiting · Washington University School of Medicine · St Louis, Missouri
- Pre-myeloid Cancer and Bone Marrow Failure Clinic StudyRecruiting · Mayo Clinic · Scottsdale, Arizona
- Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic LeukemiaPHASE2 · Recruiting · Mayo Clinic · Mankato, Minnesota
- CHIP/CCUS Natural History ProtocolRecruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland